|Bid||1,415.60 x 0|
|Ask||1,416.20 x 0|
|Day's Range||1,406.20 - 1,419.20|
|52 Week Range||1,190.80 - 1,631.60|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||13.59|
|Forward Dividend & Yield||0.80 (5.68%)|
|Ex-Dividend Date||May 20, 2021|
|1y Target Est||N/A|
Dr. Shikha Jain, Assistant Professor of Medicine, University of Illinois Chicago, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.